Objective:
To explore the potential of tyrosine kinase inhibitors (TKIs) in treating retinal vascular diseases, specifically neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), and their impact on treatment burden.
Key Findings:
- Vorolanib shows noninferior BCVA outcomes compared to aflibercept in nAMD, as demonstrated in the phase 2 DAVIO 2 trial.
- Duravyu demonstrated favorable BCVA and anatomical improvements in DME in the phase 2 VERONA trial.
- Axitinib and its formulations (OTX-TKI and CLS-AX) have shown promising results in early trials for both nAMD and DME, with ongoing phase 3 trials expected to provide further insights.
- Topical TKI PAN-90806 reduced injection burden significantly in nAMD patients, with 51% not requiring rescue injections.
- D4517.2 (migaldendranib) showed substantial reductions in treatment burden in nAMD and DME, pending further validation in ongoing trials.
Interpretation:
TKIs represent a promising advancement in the treatment of retinal vascular diseases, potentially offering improved efficacy and reduced treatment burden compared to traditional therapies.
Limitations:
- No TKIs are currently commercially available, which limits immediate clinical application.
- Ongoing trials may have varying endpoints and timelines, affecting the availability of results and their generalizability.
Conclusion:
The development of TKIs could significantly alter treatment paradigms for retinal vascular diseases, pending further clinical validation through ongoing trials such as those for Duravyu and Axitinib.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.